Clinical trial · Interventional
Early Palliative Care and Hematological Cancer Patients
Early Palliative Care and Hematological Cancer Patients: a Phase II Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow accrual
Summary
Brief summary (as posted)
The aim of the study is to pilot and evaluate a new integration model between a Specialised Palliative Care (SPC) intervention and standard hematological care in an Italian hospital. This is a feasibility mix-methods study, where a sample of advanced hematological patients are randomised to receive integrated hematological care and a SPC intervention or standard hematological care throughout the course of the predictive last active treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Neoplasms | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| early palliative care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- standard care
- description
- Patients in this arm will receive standard hematological care and palliative care on demand
- type
- EXPERIMENTAL
- label
- early palliative care
- description
- early palliative care: patients in this arm will receive integrated palliative care
- interventionNames
- Other: early palliative care
Primary outcomes (1)
- measure
- Adherence to the palliative care program assessed by percentage of patients attending palliative care visits after 3 months from the enrolment
- timeFrame
- 3 months after the enrollment
- description
- the investigators consecutively register all eligible patients (and reasons for ineligibility) both from Hematological department, patients who were asked to participate to the study (and reasons for not), patients who accepted to participate (and reasons for not). The feasibility will be achieved if \>50% of patients remain in the program in the next 3 months from the enrollment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed incurable hematological tumor; * Estimated prognosis by the hematologist more than 1 month at least; * Predictive last active treatment (chemotherapy or immunotherapy) as established by hematological team; * 18 years old; * Eastern Cooperative Oncology Group ≤ 3; * Ability to read and respond to questions in Italian; * Consent to the study Exclusion Criteria: * Existence of other co morbid disease which in the opinion of the investigator prohibits participation in the protocol; * Caregiver's absence
References
Publications (1)
- DERIVEDTanzi S, Luminari S, Cavuto S, Turola E, Ghirotto L, Costantini M. Early palliative care versus standard care in haematologic cancer patients at their last active treatment: study protocol of a feasibility trial. BMC Palliat Care. 2020 Apr 22;19(1):53. doi: 10.1186/s12904-020-00561-w. PMID 32321483